Építés alatt – nem éles oldal
Belépés
Befejeződött1/2. fázis

Intralesional HPV Vaccine for Condylomata

A legfontosabb adatok

Ki végzi
University of California, San Francisco
Hol
San Francisco (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
1/2. fázis
Résztvevők
2 fő vett részt
Kezdés
2022. ápr. 15.
Befejezés
2024. júl. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • nonavalent human papillomavirus vaccine
A regiszteradat frissítve
2025. október 2.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 8 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients of all genders aged ≥ 18 years
  • Signed informed consent form
  • Confirmed clinical diagnosis of genital condylomata with minimum of 3 genital condylomata, each measuring >3mm
  • Individuals who are able to become pregnant will be advised on the following:; All individuals who are able to become pregnant will be asked about their reproductive health, sexual activity (partners, practices, prevention of pregnancy) and be advised that administration of vaccine during pregnancy is not recommended while data collection to monitor pregnancy and infant outcomes following exposure to the papillomavirus (9-valent) vaccine is ongoing. However, based on available data, an increased risk of adverse pregnancy outcomes, specifically miscarriage or congenital anomalies, has not been observed following inadvertent administration of the papillomavirus vaccine during pregnancy. Individuals who are able to become pregnant are advised to contact us immediately and will not receive any further intralesional vaccine

Ki nem vehet részt

  • Participants' vaccination history will be reviewed at time of recruitment. Patients who have previously received any prior human papillomavirus vaccine will not be permitted to participate in this study
  • Participants will be asked about allergic reaction to yeast and vaccine components at time of recruitment. Subjects with severe allergic reactions to baker's yeast (Saccharomyces cerevisiae, a vaccine component), or other vaccine components (ie polysorbate 80, Merck amorphous aluminum hydroxyphosphate sulfate) will not be permitted to participate in this study
  • Subjects' medical history and current medications will be reviewed at time of recruitment. Subjects taking immune suppressive medications (steroids such as prednisone or dexamethasone, immunosuppressive agents such as methotrexate, azathioprine, cyclosporine, immunomodulatory agents such as apremilast, or immunomodulatory biologic agents such as adalimumab, guselkumab or ustekinumab) will be excluded. Subjects with medical conditions that significantly alter the immune system, such as known HIV infection, leukemia or lymphoma will be excluded from this pilot study
  • Participants will be asked about pregnancy at time of recruitments. Individuals who are pregnant or are planning to become pregnant will not be permitted to participate in the study, as ACOG does not recommend Gardasil 9 during pregnancy. Participants will be encouraged not to participate in the study if they believe they may become pregnant during the study

Helyszínek itt: Egyesült Államok

  • Zuckerberg San Francisco General HospitalSan Francisco, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.

A vizsgálat csoportja

  • Intralesional injection of nonavalent human papillomavirus vaccineA vizsgált kezelés

    Single-arm, open-label study. Intervention consists of intralesional injection of nonavalent human papillomavirus vaccine at 0 and 4 weeks.

    Kezelés: nonavalent human papillomavirus vaccine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Therapeutic Intralesional Nonavalent HPV Vaccine for Genital Condylomata in Adults: an Open Label Pilot Study
A regiszteradat frissítve
2025. október 2.